**South African National Essential Medicines List**

**Pricing Analysis**

**Name of STG ERC**

**Component: STG chapter and section**

**Generic name of health technology and relevant indication (e.g. x for treating x)**

**Date**

# EXECUTIVE SUMMARY

|  |
| --- |
| **Medicine:**  **Indication:**  **Research question:**  **Level of Care:**  **Current Standard of Care/ Comparator(s):**  **Methods:**  **Findings:**  **Reviewers:**  **PTC affiliation:**  **Disclosures:**  **Funding support:** |

**NAMES OF REVIEWERS**

**AFFILIATION AND CONFLICT OF INTEREST**

Potential conflict of interest statement included here.

Official form should be completed and sent to EDP prior to undertaking the review.

# INTRODUCTION

Brief description of the following information:

* Rationale for why this type of analysis has been selected
* Brief description of the treatment alternatives already available in the South African public health sector (reference Standard Treatment Guidelines and other Department of Health clinical guidelines, if relevant).

# International pricing analysis

Brief outline of pricing identification strategy.

Show results for each medicine (new and comparators) for each relevant strength and formulation and calculate price per daily dose for HTA topic.

Compare prices across countries in the same price type (e.g. reimbursement value) for the new medicine and comparators. Averages costs per price type can be determined with either the median or mean values depending on number of values available. See example table below.

**Example - Table x**: International Price Comparison of New Medicine A, Comparator 1, and Comparator 2 in strength (e.g. 30mg) and formulation (e.g. oral tablet) for Condition Y.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ex-Manufacturer Price | | | | | | |
|  | **New Medicine** | | **Comparator 1** | | **Comparator 2** | |
|  | Price | ZAR | Price | ZAR | Price | ZAR |
| *Country 1* |  |  |  |  |  |  |
| *Country 2* |  |  |  |  |  |  |
| *Add more rows if needed* |  |  |  |  |  |  |
| AVERAGE PRICE |  | R |  | R |  | R |
| References: (include date the exchange rate was obtained) | | | | | | |
| Reimbursement Value | | | | | | |
|  | **New Medicine** | | **Comparator 1** | | **Comparator 2** | |
|  | Price | ZAR | Price | ZAR | Price | ZAR |
| *Country 1* |  |  |  |  |  |  |
| *Country 2* |  |  |  |  |  |  |
| *Add more rows if needed* |  |  |  |  |  |  |
| AVERAGE PRICE |  | R |  | R |  | R |
| References: (include date the exchange rate was obtained) | | | | | | |
| Ceiling price | | | | | | |
|  | **New Medicine** | | **Comparator 1** | | **Comparator 2** | |
|  | Price | ZAR | Price | ZAR | Price | ZAR |
| *Country 1* |  |  |  |  |  |  |
| *Country 2* |  |  |  |  |  |  |
| *Add more rows if needed* |  |  |  |  |  |  |
| AVERAGE PRICE |  | R |  | R |  | R |
| References: (include date the exchange rate was obtained) | | | | | | |
| Wholesale price | | | | | | |
|  | **New Medicine** | | **Comparator 1** | | **Comparator 2** | |
|  | Price | ZAR | Price | ZAR | Price | ZAR |
| *Country 1* |  |  |  |  |  |  |
| *Country 2* |  |  |  |  |  |  |
| *Add more rows if needed* |  |  |  |  |  |  |
| AVERAGE PRICE |  | R |  | R |  | R |
| References: (include date the exchange rate was obtained) | | | | | | |

# Local pricing analysis

Show results for each comparator for each relevant strength and formulation and calculate price per daily dose for HTA topic (see example below). Include Single Exit Price (SEP) as well as contract price on Master Health Product List.

Use the difference between SEP and Master Health Product List price of comparator treatments to calculate the estimated discount that might be achieved.

**Example Table x**: Local price comparison for Comparator 1 and 2 for relevant strengths and formulations for Condition Y per daily dose.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Proprietary Name | Strength | Formulation | Contract Price (MPC) | Single Exit Price (SEP) |
| Comparator 1 | E.g. 20mg | Injection | R | R |
| E.g. 40mg | Injection | R | R |
| E.g. 60mg | Injection | R | R |
| Comparator 2 | E.g. 20mg | Injection | R | R |
| E.g. 40mg | Injection | R | R |
| E.g. 60mg | Injection | R | R |
| Estimated discount achieved on contract price = x % | | | | |

Show results for new medicine for relevant strength and formulation and calculate price per daily dose for HTA topic (see example below). Estimated contract price can be calculated by applying the average discount achieved with comparators determined above to the SEP.

**Example Table x**: Local price comparison for New Medicine for relevant strengths and formulations for Condition Y per daily dose.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Proprietary Name | Strength | Formulation | Single Exit Price (MRP) | Average Discount | Estimated Contract Price |
| New Medicine | E.g. 20mg | Injection | R | X % | R |
| E.g. 40mg | Injection | R | R |
| E.g. 60mg | Injection | R | R |

Prices for the new medicine (estimated contract price, SEP) and comparators (current contract price and SEP) can then be compared to the international averages produced in the international comparison analysis (see example below).

**Example Table x:** Local and international price comparison for New Medicine and Comparators for relevant strengths and formulations for Condition Y per daily dose.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Proprietary Name | Strength | Formulation | Single Exit Price (MRP) | Contract Price | International Average |
| New Medicine | E.g. 20mg | Injection | R | R | R |
| E.g. 40mg | Injection | R | R | R |
| E.g. 60mg | Injection | R | R | R |
| Comparator 1 | E.g. 20mg | Injection | R | R | R |
| E.g. 40mg | Injection | R | R | R |
| E.g. 60mg | Injection | R | R | R |
| Comparator 2 | E.g. 20mg | Injection | R | R | R |
| E.g. 40mg | Injection | R | R | R |
| E.g. 60mg | Injection | R | R | R |

# Active pharmaceutical ingredient global supply analysis

List active manufacturers producing the medicine under assessment as well as any potential issues related to supply of technologies globally and in South Africa.

Information on country of producer, name of producer and which strengths and formulations are produced must be tabled as in the example below.

**Example Table x:** Producers of New Medicine and Comparators in each relevant strength and formulation

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Strength | Formulation | Name of producer | Country |
| New Medicine | E.g. 20mg | Injection |  |  |
| E.g. 40mg | Injection |  |  |
| E.g. 60mg | Injection |  |  |
| Comparator 1 | E.g. 20mg | Injection |  |  |
| E.g. 40mg | Injection |  |  |
| E.g. 60mg | Injection |  |  |
| Comparator 2 | E.g. 20mg | Injection |  |  |
| E.g. 40mg | Injection |  |  |
| E.g. 60mg | Injection |  |  |

# References

Vancouver style format